Osteoarthritis Pain - Pipeline Review, H2 2014

Global Markets Direct
July 31, 2014
140 Pages - SKU: GMD5310009
Osteoarthritis Pain - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Osteoarthritis Pain - Pipeline Review, H2 2014’, provides an overview of the Osteoarthritis Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Osteoarthritis Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Additional Information

Companies Mentioned

Boehringer Ingelheim GmbH
Allergan, Inc.
Eli Lilly and Company
Pfizer Inc.
Purdue Pharma L.P.
Teva Pharmaceutical Industries Limited
BioChemics, Inc.
Addex Therapeutics Ltd
Nuvo Research Inc.
Pozen, Inc.
Futura Medical plc
AcurePharma AB
Rottapharm SpA
QRxPharma Limited
Iroko Pharmaceuticals, LLC
Antibe Therapeutics, Inc.
Flexion Therapeutics, Inc.
Afferent Pharmaceuticals, Inc.
iCeutica, Inc.
Ampio Pharmaceuticals, Inc.
AbbVie Inc.
Akron Molecules AG

Country

Global

Sector

Central Nervous System

More Drug Discovery reports by Global Markets Direct

Chronic Pain - Pipeline Review, H2 2014 by Global Markets Direct
Chronic Pain - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Chronic Pain - Pipeline Review, H2 2014’, provides an overview of the Chronic Pain’s therapeutic pipeline.This ...
Malaria - Pipeline Review, H2 2014 by Global Markets Direct
Malaria - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Malaria - Pipeline Review, H2 2014’, provides an overview of the Malaria’s therapeutic pipeline.This report provides comprehensive ...
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014 by Global Markets Direct
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 ...
Primary Dysmenorrhea - Pipeline Review, H2 2014 by Global Markets Direct
Primary Dysmenorrhea - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Primary Dysmenorrhea - Pipeline Review, H2 2014’, provides an overview of the Primary Dysmenorrhea’s therapeutic pipeline.This ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 2,000  
    Site License  USD 4,000  
    Global Site License  USD 6,000  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!